A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator\'s choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.
Epistemonikos ID: cb64508901e57508be28229ecfeb72f1807f4117
First added on: Aug 01, 2024